Oxyresveratrol

Oxyresveratrol (trans-Oxyresveratrol) is a potent naturally occurring antioxidant and free radical scavenger (IC50 of 28.9 µM against DPPH free radicals). Oxyresveratrol is potent and noncompetitive tyrosinase inhibitor with an IC50 value of 1.2 µM for mushroom tyrosinase. Oxyresveratrol is effective against HSV-1, HSV-2 and varicella-zoster virus, and has neuroprotective effects.

Product information

CAS Number: 29700-22-9

Molecular Weight: 244.24

Formula: C14H12O4

Chemical Name: 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol

Smiles: OC1C=C(O)C(/C=C/C2C=C(O)C=C(O)C=2)=CC=1

InChiKey: PDHAOJSHSJQANO-OWOJBTEDSA-N

InChi: InChI=1S/C14H12O4/c15-11-4-3-10(14(18)8-11)2-1-9-5-12(16)7-13(17)6-9/h1-8,15-18H/b2-1+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 50 mg/mL (204.72 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Cultures of the murine microglial cell line N9 and primary mixed glial cultures were used to test the drug effects of NO production upon expression of the inducible isoform of nitric oxide synthase (iNOS). Oxyresveratrol considerably diminished NO (nitrite) levels (IC50 of 45.31 µM) in murine microglial cells. Oxyresveratrol can inhibit DOPA oxidase activity, cyclooxygenase, and rat liver mitochondrial ATPase activity. Oxyresveratrol exhibits 63.3% inhibition at 100 µM and an IC50 value of 52.7 µM on the murine tyrosinase activity. Oxyresveratrol exhibits a dose-dependent inhibitory effect on L-tyrosine oxidation by the murine tyrosinase but does not inhibit the promoter activity of the enzyme gene. Oxyresveratrol exhibits significant inhibitory effects at 10 µM and higher concentrations on murine tyrosinase activity.

In Vivo:

Oxyresveratrol (2-30 mg/kg; intraperitoneal injection; twice) treatment reduces the brain infarct volume in MCAO rats. Oxyresveratrol treatment diminishes cytochrome c release and decreased caspase-3 activation, and reduces the number of apoptotic nuclei in ischemic brain in MCAO rats.

Products are for research use only. Not for human use.